Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod for recovery after traumatic spinal cord injury
IRCT20240701062291N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in spinal cord injury (SCI) and acute spinal cord injury (SCI) comparing Methylprednisolone + fingolimod with Methylprednisolone + placebo (2 arms). Primary endpoints: Sensorimotor status and Sphincter status. Started Aug 2024; status: completed.
02
Drugs
fingolimod
03
Conditions
spinal cord injury (SCI)acute spinal cord injury (SCI)
Beyond the preview
Go deeper on IRCT20240701062291N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240701062291N1.